• Policy
• Akynzeo is licensed domestically
• by Kim, Jung-Ju Nov 3, 2022 05:54am

• Policy
• NHI big data was used to evaluate safety of JAK inhibitors
• by Lee, Tak-Sun Nov 2, 2022 05:36am

• Policy
• "Synthetic Biology" that Moderna used
• by Kang, Shin-Kook Nov 2, 2022 05:36am

• Policy
• LG Chemical completed Vimovo's domestic copyright
• by Lee, Tak-Sun Nov 1, 2022 06:02am

• Policy
• It doesn't mean that we're considering a reduction
• by Lee, Tak-Sun Nov 1, 2022 06:02am

• Policy
• Gov’t to fully investigate its COVID-19 research support
• by Lee, Tak-Sun Nov 1, 2022 06:02am

• Policy
• It takes 218 days to register after applying for a new drug
• by Kim, Jung-Ju Oct 31, 2022 06:07am

• Policy
• Koselugo & Retevmo's benefit registration can be shortened
• by Lee, Tak-Sun Oct 31, 2022 06:06am

• Policy
• The warning phrase deleting the possibility of Nucynta abuse
• by Lee, Hye-Kyung Oct 27, 2022 05:52am

• Policy
• Permission for Libtayo, a tx for skin squamous cell cancer
• by Lee, Hye-Kyung Oct 26, 2022 05:50am